Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 23

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jun 21, 2024; 30(23): 2964-2980
Published online Jun 21, 2024. doi: 10.3748/wjg.v30.i23.2964

Table 2 The influence of the type of treatment on the comparison of gut microbiota

Bacteria levels	GLP-1 RAs	GLP-1/GLP-2 RA	Roux-en-Y gastric bypass surgery
Increase	Bifidobacteriaceae	Bifidobacteriaceae	Bacteroidetes
	Actinobacteria	Prevotellaceae	Actinobacteria
	Akkermansiaceae	Lactobacillaceae	Proteobacteria
		Akkermansiaceae	Akkermansiaceae
Decrease	Firmicutes	Firmicutes	Firmicutes
	Oscillospiraceae		Oscillospiraceae
	Bacteroidetes
Microbiota diversity	Increase	Increase	Increase

GLP-1 RAs: Glucagon-like peptide-1 receptor agonists; GLP-1/GLP-2 RA: Dual glucagon-like peptide-1 and glucagon-like peptide-2 receptor agonist.

Citation: Rochoń J, Kalinowski P, Szymanek-Majchrzak K, Grąt M. Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease. World J Gastroenterol 2024; 30(23): 2964-2980
URL: https://www.wjgnet.com/1007-9327/full/v30/i23/2964.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i23.2964

Rochoń J, Kalinowski P, Szymanek-Majchrzak K, Grąt M. Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease. World J Gastroenterol 2024; 30(23): 2964-2980 [PMID: 38946874 DOI: 10.3748/wjg.v30.i23.2964]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.